Company news
Eyepoint, Inc. (NASDAQ:EYPT) news
Every Eyepoint, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
August 5, 2026
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
July 30, 2026
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
July 13, 2026
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of M...
May 14, 2026
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
May 6, 2026
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
March 4, 2026
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
March 2, 2026
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
February 25, 2026
EyePoint Appoints Michael Campbell as Chief Commercial Officer
February 18, 2026
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 16, 2026
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
January 7, 2026
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in W...
November 19, 2025
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
November 5, 2025
EyePoint Announces Participation at Upcoming Investor Conferences
November 3, 2025
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
October 29, 2025
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
October 14, 2025
EyePoint Announces Proposed Public Offering of Common Stock
October 14, 2025
EyePoint Announces Pricing of Public Offering
October 14, 2025
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
August 6, 2025
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 6, 2025
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
July 29, 2025
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
May 27, 2025
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 16, 2025
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
May 7, 2025
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
April 30, 2025
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
March 27, 2025
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments
March 5, 2025
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
February 26, 2025
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
February 25, 2025
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primar...
February 5, 2025
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
January 30, 2025
EyePoint Provides Company Update and Anticipated Development Milestones for 2025
January 13, 2025
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
January 8, 2025
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Mac...
December 4, 2024
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
November 7, 2024
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
November 4, 2024
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
October 31, 2024
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
October 29, 2024
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macul...
October 28, 2024
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 28, 2024
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-...
October 24, 2024
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
September 4, 2024
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 8, 2024
EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments
August 7, 2024
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation ...
June 26, 2024